Study S001126

Effects of Semaglutide on Nicotine Intake and Smoking Lapse

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)Informed Consent Form (PDF)

Registration

Registration: NCT05530577
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 24
Start: 2022-10-07
Primary completion: 2024-05-13
Lead sponsor: University of North Carolina, Chapel Hill
Conditions: Tobacco Use Disorder; Nicotine Addiction
Interventions: DRUG:Semaglutide; DRUG:Sham/placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: NIH:R21DA047663-02

Registered primary outcomes

Change in Nicotine Self-Administration [Baseline (Week 0) to post-medication (Week 8)]
Change in Nicotine Reinstatement Duration [Baseline (Week 0) to post-medication (Week 8)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0003312	Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial. Hendershot CS, JAMA network open	2026	Randomized trial	PMID 42189538 DOI	cites ClinicalTrials.gov:NCT05530577; registry reference DERIVED:42189538